15-巯基-4,7,10,13-四氧杂十五烷酸叔丁酯 | 564476-33-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 15-巯基-4,7,10,13-四氧杂十五烷酸叔丁酯
• 中文别名: 巯基四聚乙二醇缬氨酸叔丁酯；15-巯基-4,7,1,13-四氧杂十五烷酸叔丁酯
• 英文名称: 15-mercapto-4,7,10,13-tetraoxapentadecanoic acid tert-butyl ester
• 英文别名: Thiol-PEG4-t-butyl ester；tert-butyl 3-[2-[2-[2-(2-sulfanylethoxy)ethoxy]ethoxy]ethoxy]propanoate
• CAS: 564476-33-1
• 化学式: C₁₅H₃₀O₆S
• 分子量: 338.466
• InChiKey: NKLWGDQDZRFINM-UHFFFAOYSA-N

物化性质

• 沸点：
  414.6±40.0 °C(Predicted)
• 密度：
  1.060±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  22
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  64.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  15-巯基-4,7,10,13-四氧杂十五烷酸叔丁酯 在 三乙基硅烷 、 sodium phosphate buffer 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 3-[2-[2-[2-[2-(甲基二硫烷基)乙氧基]乙氧基]乙氧基]乙氧基]丙酸
  参考文献：
  名称：

  Synthesis of Taxoids with Improved Cytotoxicity and Solubility for Use in Tumor-Specific Delivery

  摘要：

  To develop effective taxane-antibody immunoconjugates, we have prepared a series of modified taxanes that have both improved toxicity and solubility in aqueous systems as compared to paclitaxel (1a). These taxanes have been modified at either the C-10 or C-7 position and were found to be very cytotoxic against both normal and multi-drug-resistant (MDR) cells, as well as up to 30 times more soluble than paclitaxel in various buffer systems.

  DOI：

  10.1021/jm049705s
• 作为产物：
  描述：

  PEG5-羧酸叔丁酯,HO-PEG4叔丁酯,1-羟基-3,6,9,12-四氧杂十五烷-15-酸叔丁酯 在 hydroxylamine buffer 、 三乙胺 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 10.5h， 生成 15-巯基-4,7,10,13-四氧杂十五烷酸叔丁酯
  参考文献：
  名称：

  Synthesis of Taxoids with Improved Cytotoxicity and Solubility for Use in Tumor-Specific Delivery

  摘要：

  To develop effective taxane-antibody immunoconjugates, we have prepared a series of modified taxanes that have both improved toxicity and solubility in aqueous systems as compared to paclitaxel (1a). These taxanes have been modified at either the C-10 or C-7 position and were found to be very cytotoxic against both normal and multi-drug-resistant (MDR) cells, as well as up to 30 times more soluble than paclitaxel in various buffer systems.

  DOI：

  10.1021/jm049705s

文献信息

• CYTOTOXIC AGENTS BEARING A REACTIVE POLYETHYLENE GLYCOL MOIETY, CYTOTOXIC CONJUGATES COMPRISING POLYETHYLENE GLYCOL LINKING GROUPS, AND METHODS OF MAKING AND USING THE SAME
  申请人：ImmunoGen, Inc.

  公开号：US20040001838A1

  公开（公告）日：2004-01-01

  Cytotoxic agents bearing a polyethylene glycol (PEG) linking group having a terminal active ester, cytotoxic conjugates comprising one or more cytotoxic agents linked to a cell-binding agent via PEG linking groups, and methods for producing both are disclosed. A therapeutic composition comprising a therapeutically-effective amount of one of the cytotoxic conjugates of the present invention, and a method of killing selected cell populations comprising contacting target cells, or tissue containing target cells, with an effective amount of one of the cytotoxic conjugates, are also disclosed.

  本文披露了带有具有末端活性酯的聚乙二醇（PEG）连接基团的细胞毒性药物、包括通过PEG连接基团将一种或多种细胞毒性药物与细胞结合剂连接的细胞毒性结合物，以及生产这两种物质的方法。还披露了一种治疗组合物，包括本发明的一种细胞毒性结合物的治疗有效量，并且披露了一种杀灭选定细胞群的方法，包括将靶细胞或含有靶细胞的组织与一种细胞毒性结合物的有效量接触。
• Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
  申请人：Immunogen Inc.

  公开号：US06716821B2

  公开（公告）日：2004-04-06

  Cytotoxic agents bearing a polyethylene glycol (PEG) linking group having a terminal active ester, cytotoxic conjugates comprising one or more cytotoxic agents linked to a cell-binding agent via PEG linking groups, and methods for producing both are disclosed. A therapeutic composition comprising a therapeutically-effective amount of one of the cytotoxic conjugates of the present invention, and a method of killing selected cell populations comprising contacting target cells, or tissue containing target cells, with an effective amount of one of the cytotoxic conjugates, are also disclosed.

  本发明公开了具有末端活性酯的聚乙二醇（PEG）连接基的细胞毒素药剂，包括通过PEG连接基将一种或多种细胞毒素药剂与细胞结合剂连接的细胞毒素结合物，以及制备这两种物质的方法。本发明还公开了治疗组合物，包括本发明的一种细胞毒素结合物的治疗有效量，以及一种杀死选定细胞群的方法，包括用一种细胞毒素结合物的有效量接触目标细胞或含有目标细胞的组织。
• EP1463558A4
  申请人：——

  公开号：EP1463558A4

  公开（公告）日：2007-10-31
• CYTOTOXIC AGENTS COMPRISING POLYETHYLENE GLYCOL-CONTAINING TAXANES AND THEIR THERAPEUTIC USE
  申请人：Immunogen, Inc.

  公开号：EP1506181A1

  公开（公告）日：2005-02-16
• EP1506181A4
  申请人：——

  公开号：EP1506181A4

  公开（公告）日：2006-11-08